After thriving on the market for more than a decade as the only treatment for Dupuytrens contracture and Peyronie’s disease, Keenova Therapeutics’ Xiaflex has excelled in a phase 3 trial that could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results